Autolus Therapeutics Plc ADR AUTL

$1.60 -0.12 (-6.98%)

Valuation

Market cap
425,861,000
Revenue TTM
$75,390,000
Net income TTM
$-287,530,000
PE ratio
0.00
Forward PE
—
Profit margin
-381.39%
Debt to equity
0.00

Trading

Volume
2,350,600
Avg volume
2,101,088
Day's range
$1.59 – $1.74
Shares out
266,163,000
Stochastic %K
4%
Beta
2.15
Analysts
Strong Sell
Price target
$8.69

Price

Company profile

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases in the United Kingdom and internationally. The company offers AUCATZYL, a gene therapy product consisting of autologous T cells that are transduced with a lentiviral vector to express a novel anti-CD19 chimeric antigen receptor. It also develops obe-cel, which is in phase...

Show more

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases in the United Kingdom and internationally. The company offers AUCATZYL, a gene therapy product consisting of autologous T cells that are transduced with a lentiviral vector to express a novel anti-CD19 chimeric antigen receptor. It also develops obe-cel, which is in phase 1 to treat systemic lupus erythematosus, progressive multiple sclerosis, B-NHL and CLL, and CNS lymphoma; obe-cel, which is in phase 2 to treat pediatric B-ALL and lupus nephritis; AUTO1/22 to treat pediatric B-ALL, which is phase 1; AUTO8, which is in phase 1 to treat multiple myeloma and light chain amyloidosis; AUTO4/5, which is in preclinical stage to treat peripheral TCL; AUTO6NG, which is in phase 1 to treat neuroblastoma; and AUTO9, which is in preclinical stage to treat acute myeloid leukemia. The company was incorporated in 2014 and is headquartered in London, the United Kingdom.

Industry
Biotechnology
Sector
Healthcare
Phone
44 20 3829 6230
Website
https://www.autolus.com
Address
The Mediaworks, 191 Wood Lane White City, London, United Kingdom

Latest news

Stocktwits

Merlintrader Oct 18, 2:41 PM
$AUTL daily chart Friday: closed -7.0% at $1.60 on 2.35M shares (1.1x avg). News (Oct 5, GlobeNewswire): longer CARLYSLE lupus follow-up set for ACR 2026. Support $1.17 (52w low) | resistance $1.68 (200d SMA). Next catalyst: CARLYSLE and ALARIC data by year-end (window). Full hub: https://www.merlintrader.com/autolus-therapeutics-stock-hub/ Not investment advice.
0 replies
diggs24 Oct 16, 8:19 PM
$AUTL Added 4000.
0 replies
Michael_garic Oct 16, 8:12 PM
$AUTL one eighth of the day's trading was in the last thirty minutes. Sellers tried to keep the close below 1.60 but 100K worth of bids came in at the last minute and moved the price back up. A lot of noise before the earnings. Rebalancing should tail off, options are done for now, so maybe we can get back to normal trading sessions instead of these nightly tug of wars.. Q3 earnings will be out soon and we will see where we all stand with AUTL.
0 replies
NANANANANANANAN Oct 16, 7:56 PM
$AUTL
1 replies
cowneck_trader Oct 16, 6:26 PM
$AUTL bought at 1.61 less than 2 weeks ago. I guess they want me to more. Thank you.
1 replies
diggs24 Oct 16, 4:12 PM
$AUTL Bring it back to $1.60 for me bb.
0 replies
TricksterT Oct 16, 3:14 PM
$AUTL accumulate. Market is choppy but this one is going to have its day very soon.
1 replies
Prindle Oct 16, 1:45 PM
$AUTL this is a buy, not a stock you’d sell.
0 replies